Why Are Twist Bioscience Shares Plunging Today?


Twist Bioscience Corporation TWST reported a 17% Y/Y increase in its Q4 revenues to $37.95 million, beating the Wall Street estimate of $37.02 million, driven by strength in SynBio, NGS, biopharma businesses.

  • The Company shipped products to approximately 2,900 customers in fiscal 2021, versus about 2,200 in fiscal 2020.
  • The Company posted a wider net loss of $(0.84) per share, missing the consensus of $(0.79) and higher than a loss of $(0.54) posted a year ago.
  • Twist held $465.83 million in cash and cash equivalents and $12.03 million in short-term investments in Q3.
  • Acquisition: The Company also announced it is acquiring Abveris for $190 million. Abveris offers comprehensive antibody discovery and characterization services.
  • FY22 Guidance: Twist expects sales of $173 million - $181 million without Abveris (consensus) and $183 million - $193 million, including Abveris.
  • This includes synthetic biology revenue of $67 million - $70 million, NGS revenue of $94 million - $96 million. 
  • The Company expects an FY22 adjusted gross margin of 42% - 44%.
  • For Q1 FY22, Twist forecast sales of $37 million - $39 million (consensus of $38.78 million).
  • Price Action: TWST shares are down 7.44% at $102.39 during the market session on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsM&ANewsGuidanceHealth CareMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!